CagriSema Clinical Trials Evidence CagriSema's evidence base is unusually strong for a peptide research stack: two large Phase 3 trials with NEJM publications, plus Phase 1b/2 supporting data
It is estimated that 25% of the global population has NAFLD, a number projected to continue to rise, and as it does, it is expected that more of these cases will progress to end-stage disease states requiring liver transplantation
Research has shown that the benefits of supplementing with L-Glutathione may include
Key Highlights: 250mg of Setria Glutathione per capsule (the world's most bioavailable form) 100mg Sulfodyne Sulforaphane (7x better absorption than standard extracts) Pharmaceutical-grade formulation made in Europe Third-party tested for purity and heavy metals Vegan, non-GMO, and free from common allergens Backed by clinical research showing 38% reduction in oxidative stress What makes The Protect superior is its dual-action formula
L.KuiperN
This is the longer, more clinical version, for anyone out there who wants the science on peptides alone (apart from surgery) as an anti-aging modality, presented in plain English